LY2228820 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of p38 MAPK (mitogen-activated protein kinase), a signaling pathway involved in cellular responses to stress and inflammation. By targeting this pathway, LY2228820 aims to disrupt the growth and survival of cancer cells, particularly in tumors where p38 MAPK activity is elevated. Research has explored its use in combination with other chemotherapeutic agents to enhance treatment efficacy, especially in resistant or aggressive cancers. Additionally, its role in modulating tumor microenvironment and reducing inflammation-related tumor progression is of significant interest in preclinical and clinical studies.